Aug 2026· In Vivo· Vol 40, pp. 3106 - 3118· 0 citations· 19 references
Medicine
Abstract
Background/Aim: Maintaining treatment intensity is important during adjuvant S-1 chemotherapy for resectable pancreatic cancer; however, factors associated with reduced relative dose intensity (RDI) during adjuvant chemotherapy (AC) remain unclear. This study investigated the association between perioperative inflammatory and nutritional indices and the RDI of S-1 during AC. Patients and Methods: This retrospective single-center study included 69 patients with resectable pancreatic cancer who underwent adjuvant S-1 chemotherapy following neoadjuvant chemotherapy (NAC) and pancreatectomy between November 2019 and February 2025. Patients were classified according to AC S-1 RDI (≥80% vs. <80%). Inflammatory and nutritional indices, as well as changes in prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) from NAC initiation to AC initiation, were compared between the groups. Results: AC S-1 RDI was significantly associated with overall survival and recurrence-free survival (both p=0.02), and patients with RDI ≥80% had significantly better overall survival than those with RDI <80% (p=0.02). At AC initiation, PNI and GNRI were significantly higher in the RDI ≥80% group than in the RDI <80% group. Changes in PNI and GNRI from NAC initiation to AC initiation were also more favorable in the RDI ≥80% group. On multivariate analysis, these nutritional indices were associated with maintenance of RDI ≥80% for S-1 as AC. Receiver operating characteristic analysis showed that GNRI at AC initiation had the highest predictive performance for reduced AC S-1 RDI (<80%) (area under the curve = 0.77; optimal cut-off of 98.7). Conclusion: Nutritional status at AC initiation and perioperative changes in nutritional status were associated with maintenance of AC S-1 RDI in patients with resectable pancreatic cancer. The GNRI at AC initiation may be useful for assessing the risk of reduced S-1 RDI during AC.
Background/Objectives: While perioperative chemotherapy is standard for locally advanced gastric cancer, no baseline blood marker reliably identifies which patients will respond to treatment. In this retrospective study, we compared eleven inflammatory and nutritional indices against pathological response and survival...
Erkut Demirciler, K. Canaslan, H. I. Ellez et al.· Journal of Clinical Medicine· 0 citations
OBJECTIVES
The cachexia index (CXI), integrating skeletal muscle mass, serum albumin, and the neutrophil-to-lymphocyte ratio, has been proposed as a marker of cancer-related cachexia. The objective of this study was to assess the prognostic significance of pre-treatment CXI in patients with resectable or borderline res...
Satoru Tsuruta, K. Ishido, H. Nagase et al.· Pancreas· 0 citations
Background/Aim: Pretreatment nutritional and inflammatory indices have been associated with prognosis in patients with oral squamous cell carcinoma (OSCC) undergoing surgery or chemoradiotherapy; however, their prognostic significance in patients treated with superselective intra-arterial infusion of cisplatin and conc...
Akemi Ohtani, Masato Saito, Tomokazu Hasegawa et al.· In Vivo· 0 citations
BACKGROUND
Perioperative chemotherapy is standard of care for resectable gastric cancer (GC), but many patients do not complete adjuvant chemotherapy (AC). It remains unclear whether AC following neoadjuvant chemotherapy (NAC) improves survival. We sought to assess differences in survival between patients with resectab...
Aravind Sreeram, Celine Yeh, N. Toumbacaris et al.· The Oncologist· 0 citations
Background/Aim: Neoadjuvant chemotherapy with gemcitabine plus S-1 (NAC–GS) is used for resectable pancreatic cancer, but adverse events prevent some patients from completing planned therapy. This study examined associations of pretreatment absolute neutrophil count (ANC) and prognostic nutritional index (PNI) with NAC...
Hiroo Suto, Hibiki Sakai, AN Fujita et al.· Anticancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.